A syngeneic murine and mutant KRAS-driven lung cancer model used to investigate tumour immunology, immune checkpoint inhibitors, and KRAS-targeted therapies. Save 30% on this cell line this autumn. Use code ACA26CELL at checkout.
| Inventor | Institute |
|---|---|
| Julian Downward, Jesse Boumelha, Sophie de Carne | The Francis-Crick Institute |
| SKU: | 161803 |
|---|---|
| Product description: | KPAR1.3 cells (also called KPAR) are a single cell clone derived from a cell line isolated from a lung tumour of KRASLSL-G12D/+; Trp53fl/fl;Rosa26A3Bi; Rag1-/- mice. Although cell line is derived from a heterozygous KRAS-G12D/WT model, the cell line is homozygous for the mutation. Mouse models of mutant KRAS-driven lung cancer with an elevated tumour mutational burden by expressing the human DNA cytosine deaminase, APOBEC3B, to mimic the mutational signature seen in human lung cancer. The ability of KRAS/KRASG12 inhibitors to cause regression of KRASG12C expressing tumours was markedly potentiated by the adaptive immune system. |
| Alternate name: | |
| CRISPR: | No |
| Production details: | Single cell clone from a cell line isolated from KrasLSL-G12D/+; Trp53fl/fl; Rosa26A3Bi;Rag1–/– mouse (KPAR) lung tumours |
| Model description: | Single cell clone from a cell line isolated from KrasLSL-G12D/+; Trp53fl/fl; Rosa26A3Bi;Rag1–/– mouse (KPAR) lung tumours |
| Products or characteristics of interest: | |
| Related tools: |
| Cat. #: | 161803 |
|---|---|
| Cancer types: | Lung cancer |
| Research Fields: | Cancer |
| Organism: | Mouse |
| Tissue: | Lung |
| Model: | Mutant |
| Primary citation: | Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804. |
| Initial handling information: | |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM media supported with 10% FBS, glutamine and penicillin/streptomycin |
| Subculture routine: | |
| Temperature: | |
| Atmosphere: | |
| Storage medium: | |
| Recommended controls: | |
| Biosafety level: | 1 |
| References: |
Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.